Atrophy measured on structural magnetic resonance imaging (sMRI) is a powerful biomarker of the stage and intensity of the neurodegenerative aspect of Alzheimer's disease (AD) pathology. In this review, we will discuss the role of sMRI as an AD biomarker by summarizing (a) the most commonly used methods to extract information from sMRI images, (b) the different roles in which sMRI can be used as an AD biomarker, and (c) comparisons of sMRI with other major AD biomarkers.
|Original language||English (US)|
|Journal||Alzheimer's Research and Therapy|
|State||Published - 2010|
ASJC Scopus subject areas
- Clinical Neurology
- Cognitive Neuroscience